About Dyne Therapeutics, Inc. - Common Stock (DYN)
Dyne Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for patients with serious muscle diseases, particularly those caused by genetic mutations. The company leverages its proprietary Dynamic™ approach to design and deliver targeted medicines that can modulate gene expression and address the underlying causes of these conditions. By utilizing advanced technologies, Dyne aims to provide transformative treatment options that enhance the quality of life for individuals affected by muscle disorders, while also advancing its pipeline of therapeutic candidates through various stages of development. Read More
WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.
- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p<0.0001), replicating the same 7-fold change from baseline previously observed at the registrational dose -
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it plans to announce topline clinical results from the Registrational Expansion Cohort (REC) of the Phase 1/2 DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) on December 8, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event.
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an eight-year high. The dramatic ascent follows the announcement of overwhelmingly positive top-line results from its pivotal Phase 3 HOPE-3 study for
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. Accelerated Approval in Q2 2026 -
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company.
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 -
WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
